NCT00238875

A Phase II Study of Stereotactic Body Radiation Therapy in Patients With T1N0M0 Non-small Cell Lung Cancer (JCOG0403)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 167 (actual)
• Sponsor: Haruhiko Fukuda · Academic / Other
• Sex: All
• Age: 20 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of SBRT for T1N0M0 non-small cell lung cancer

Detailed description

To evaluate the efficacy and safety of SBRT for T1N0M0 non-small cell lung cancer，the following questions should be answered. Can SRT be an alternative standard treatment modality for inoperable patients? Can SRT can be a comparable standard treatment modality with lobectomy for operable patients? 12 Gy is the daily dose at the isocenter，and 48 Gy in total by 4 fractions will be irradiated by stereotactic irradiation over 4 to 8 days.

Conditions

• T1N0M0 Non-small Cell Lung Cancer

Interventions

Type	Name	Description
PROCEDURE	stereotactic body radiation therapy	Procedure/Surgery: stereotactic body radiation therapy

Timeline

• Start date: 2004-07-01
• Primary completion: 2011-11-01
• Completion: 2011-11-01
• First posted: 2005-10-14
• Last updated: 2016-09-22

Locations

16 sites across 1 country: Japan